IP Library Granted Patent US 11,458,157
Granted Patent B2
US 11,458,157 · App. 14/364,216 · Granted Oct 4, 2022

Compositions and methods for modifying a predetermined target nucleic acid sequence

Inventors: Yoel Moshe Shiboleth (D.N. Hefer, IL); Dan Michael Weinthal (Be'er Sheva, IL)
Assignee: Targetgene Biotechnologies Ltd.
A61K31/7105A61K31/711A61K31/712A61K31/713A61K31/7115A61K31/7125A61K38/00C07K19/00C12N9/22C12N15/00C12N15/102C12N15/62C12N15/825C12N15/8213C12N15/8251C12N15/902C12N15/907A61K48/00C07K2319/01C07K2319/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,458,157
App. No.
14/364,216
Granted
Oct 4, 2022
Kind
B2
Abstract

Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.

Claims (23)

1. A method for modifying a predetermined target site within a target deoxyribonucleic acid (DNA) molecule in a plant host cell by a nucleo-protein molecular complex, the method comprising delivering to the plant host cell:

(a) a programmable polypeptide, or a nucleic acid sequence encoding the programmable polypeptide, the polypeptide comprising:

(i) an effector domain, wherein the effector domain is a nuclease; and

(ii) a linking domain that is capable of interacting with a specificity conferring nucleic acid (SCNA), wherein the linking domain is devoid of a specific target-nucleic acid binding site, and wherein (A) the linking domain directly binds the SCNA or (B) the linking domain indirectly binds the SCNA; and

(b) a synthetic specificity-conferring nucleic acid (SCNA) molecule, or a nucleic acid encoding the SCNA, the SCNA molecule comprising:

(i) a nucleotide sequence complementary to a region of the target DNA molecule; and

(ii) a recognition region capable of specifically attaching to the linking domain of the programmable polypeptide;

wherein the presence of the programmable polypeptide and the SCNA in the plant host cell enables attachment of the programmable polypeptide to the SCNA, forming in the plant host cell a nucleo-protein molecular complex, wherein the SCNA provides the specificity and binding capability of the nucleo-protein molecular complex to the predetermined target site within the target DNA molecule within the plant host cell, thereby enabling the nucleo-protein molecular complex to bind to the target DNA molecule, wherein the nucleo-protein molecular complex cleaves the target DNA molecule and wherein the nucleo-protein molecular complex does not comprise any of: an effector domain of a recombinase, digoxigenin (DIG), an anti-DIG single-chain variable fragment immunoglobin (DIG-ScFv)-DIG interaction, an antibody-antigen interaction, or a single chain antibody-antigen interaction.

2. The method of claim 1 , wherein the target DNA molecule is genomic DNA.

3. The method of claim 1 , wherein the target nucleic acid sequence is an extra-chromosomal nucleic acid sequence, selected from the group consisting of a nucleic acid in mitochondria, chloroplast, amyloplast, and chromoplast.

4. The method of claim 1 , wherein the SCNA comprises a nucleic acid molecule selected from the group consisting of a single-stranded RNA, a double-stranded RNA, or a combination thereof.

5. The method of claim 1 , wherein the interaction between the SCNA and the target DNA molecule is through base pairing selected from the group consisting of a full double helix base pairing, a partial double helix base pairing, a full triple helix base pairing, a partial triple helix base pairing, and D-loops.

6. The method of claim 1 , wherein the recognition region of the SCNA comprises a RNA secondary or tertiary structure.

7. The method of claim 1 , wherein the recognition region of the SCNA comprises a nucleotide motif capable of interacting with the linking domain of the polypeptide.

8. The method of claim 1 , wherein the association between the recognition region of the SCNA and the linking domain is a nucleic acid-protein interaction.

9. The method of claim 1 , wherein the interaction between the nucleotide motif and the linking domain is a RNA-motif-binding linking domain interaction with a RNA structure.

10. The method of claim 1 , wherein the linking domain comprises a polypeptide which binds a structural RNA motif on the SCNA.

11. The method of claim 1 , wherein the programmable polypeptide is expressed in the plant host cell.

12. The method of claim 1 , wherein the programmable polypeptide and the SCNA are expressed in the plant host cell.

13. The method of claim 1 , wherein the programmable polypeptide is expressed in the plant host cell.

14. The method of claim 1 , wherein the programmable polypeptide and the SCNA are expressed in the plant host cell.

15. The method of claim 1 , wherein the effector domain of the nucleo-protein molecular complex cleaves the target DNA molecule.

16. The method of claim 1 , wherein the linking domain indirectly binds the SCNA through a modification on the SCNA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2014
From: SHIBOLETH, YOEL MOSHE; WEINTHAL, DAN MICHAEL
To: TARGETGENE BIOTECHNOLOGIES LTD.
Reel/Frame 033074/0703 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: SHIBOLETH, YOEL MOSHE; WEINTHAL, DAN MICHAEL
To: TARGETGENE BIOTECHNOLOGIES LTD.
Reel/Frame 033070/0037 →
Continuity (2)
Provisional Application 61576423 · Dec 16, 2011
Related Publication 20150211023A1 · Jul 30, 2015